Breaking News

HRSA Sends Merck 340B Contract Pharmacy Cease and Desist Letter, Agency’s First in Seven Months

HRSA told Merck today the company's conditions on 340B pricing when hospitals and health centers use contract pharmacies are illegal and must stop or Merck could face civil monetary penalties.

The federal government told drug manufacturer Merck today its conditions on 340B pricing when hospitals and health centers use contract pharmacies are illegal and must stop, or the company could face penalties of up to $6,323 per each

Read More »

HIV/AIDS Clinics Tell FTC that PBMs Usurp 340B Discounts for Themselves

The "Man Controlling Trade" statute outside the FTC's Washington, D.C., headquarters. HIV/AIDS clinics recently submitted comments to the commission about PBMs' business practices.

Pharmacy benefit managers (PBMs) should be stopped from usurping 340B drug discounts from HIV/AIDS clinics and other safety-net providers, Ryan White Clinics for 340B Access (RWC-340B) told the U.S. Federal Trade Commission (FTC) last week.

Read More »

48 Hospitals Seek Readmission to 340B After Losing Eligibility Due to COVID-19 Pandemic

Forty eight hospitals that lost their eligibility for 340B drug discounts for reasons related to the COVID-19 pandemic are seeking reinstatement to the 340B program.

At least 48 hospitals lost their eligibility for 340B drug discounts for reasons related to the COVID-19 pandemic and are seeking reinstatement to the 340B program, HRSA says.

Please Login or Become a Paid

Read More »

Today Is Last Day for Some Hospitals to File Paperwork for 340B Reinstatement

Today is the last day for hospitals that have lost their 340B eligibility during the COVID-19 pandemic to file paperwork to be reinstated to the drug discount program.

Today is the last day for hospitals that have lost their 340B eligibility due to the COVID-19 public health emergency to file paperwork to be reinstated to the drug discount program.

Please Login or Become a

Read More »

Astellas Providing Refunds for 340B Overcharges from Q3 2020 Through Q2 2021

Astellas is issuing 340B covered entities refunds for overcharges on Xtandi and Myrbetriq for the period from Q3 2020 through Q2 2021.

Astellas Pharma is issuing 340B covered entities refunds for overcharges on three NDCs for its prostate cancer treatment Xtandi and on four NDCs for its overactive bladder medication Myrbetriq for the period from Q3 2020 through Q2 2021.

Read More »

Lilly Providing Refunds for 340B Overcharges During Q3 2019

Drug company Lilly is providing refunds for 340B overcharges on 14 NDCs during 3Q 2019.

Drug manufacturer Lilly is giving 340B covered entities refunds for overcharges on 14 NDCs during Q3 2019 after restating Medicaid average manufacturer prices and best prices “to account for lagged transactional data,” the company says on a notice on the

Read More »

Next Month’s 340B Registration Period Overlaps with Deadline for Hospitals Seeking Reinstatement

The Q2 2022 registration period for 340B overlaps with the April 14 deadline for hospitals that lost their 340B eligibility due to the COVID-19 public health emergency to file paperwork for reinstatement.

The next period for 340B registration of new covered entities, outpatient facilities, and contract pharmacies will begin tomorrow, April 1, and end on Friday, April 15.

Please Login or Become a Paid Subscriber to View this

Read More »

News Alert

HRSA Refers Boehringer Ingelheim to HHS Inspector General over its 340B Contract Pharmacy Policy

HRSA has referred Boehringer Ingelheim to the HHS Inspector General for possible imposition of civil monetary penalties over BI's conditions on 340B pricing when hospitals use contract pharmacies.

The U.S. Health Resources and Services Administration (HRSA) today turned the screws tighter on Boehringer Ingelheim (BI) over its “continued failure to provide the 340B price to covered entities utilizing contract pharmacies.”

Please Login or Become

Read More »

HRSA Invokes Contract Pharmacy Fight in Pitch for Comprehensive 340B Regulatory Power

HRSA yesterday told Congress in its budget request that it needed comprehensive regulatory authority over the 340B program to resolve the dispute over the 340B contract pharmacy program.

Congress needs to give the U.S. Health Resources and Services Administration (HRSA) comprehensive regulatory authority over the 340B program to resolve the dispute over 340B contract pharmacy program, the Biden administration said yesterday in its proposed budget—although it did so

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
×

*Sign up for news summaries and alerts from 340B Report